252 related articles for article (PubMed ID: 8501169)
1. Slow baseline growth and a good response to growth hormone (GH) therapy are related to elevated spontaneous GH pulse frequency in girls with Turner's syndrome.
Kamp GA; Kuilboer MM; Wynne HJ; Rongen-Westerlaken C; Johnson ML; Veldhuis JD; Wit JM
J Clin Endocrinol Metab; 1993 Jun; 76(6):1604-9. PubMed ID: 8501169
[TBL] [Abstract][Full Text] [Related]
2. Body composition and physical fitness are major determinants of the growth hormone-insulin-like growth factor axis aberrations in adult Turner's syndrome, with important modulations by treatment with 17 beta-estradiol.
Gravholt CH; Naeraa RW; Fisker S; Christiansen JS
J Clin Endocrinol Metab; 1997 Aug; 82(8):2570-7. PubMed ID: 9253336
[TBL] [Abstract][Full Text] [Related]
3. Decreased metabolic clearance of endogenous growth hormone and specific alterations in the pulsatile mode of growth hormone secretion occur in prepubertal girls with Turner's syndrome. Genentech Collaborative Group.
Veldhuis JD; Sotos JF; Sherman BM
J Clin Endocrinol Metab; 1991 Nov; 73(5):1073-80. PubMed ID: 1939522
[TBL] [Abstract][Full Text] [Related]
4. Improved final height in girls with Turner's syndrome treated with growth hormone and oxandrolone.
Nilsson KO; Albertsson-Wikland K; Alm J; Aronson S; Gustafsson J; Hagenäs L; Häger A; Ivarsson SA; Karlberg J; Kriström B; Marcus C; Moell C; Ritzen M; Tuvemo T; Wattsgård C; Westgren U; Westphal O; Aman J
J Clin Endocrinol Metab; 1996 Feb; 81(2):635-40. PubMed ID: 8636281
[TBL] [Abstract][Full Text] [Related]
5. Twenty-four-hour plasma growth hormone (GH) profiles, urinary GH excretion, and plasma insulin-like growth factor-I and -II levels in prepubertal children with chronic renal insufficiency and severe growth retardation.
Hokken-Koelega AC; Hackeng WH; Stijnen T; Wit JM; de Muinck Keizer-Schrama SM; Drop SL
J Clin Endocrinol Metab; 1990 Sep; 71(3):688-95. PubMed ID: 2394775
[TBL] [Abstract][Full Text] [Related]
6. Serum growth hormone (GH)-binding protein and insulin-like growth factor-I levels in Turner's syndrome before and during treatment with recombinant human GH and ethinyl estradiol.
Massa G; Bouillon R; Vanderschueren-Lodeweyckx M
J Clin Endocrinol Metab; 1992 Nov; 75(5):1298-302. PubMed ID: 1430092
[TBL] [Abstract][Full Text] [Related]
7. Growth hormone treatment in Turner's syndrome: short and long-term effects on metabolic parameters.
Haeusler G; Frisch H
Clin Endocrinol (Oxf); 1992 Mar; 36(3):247-53. PubMed ID: 1563078
[TBL] [Abstract][Full Text] [Related]
8. Specific, time-dependent actions of low-dose ethinyl estradiol administration on the episodic release of growth hormone, follicle-stimulating hormone, and luteinizing hormone in prepubertal girls with Turner's syndrome.
Mauras N; Rogol AD; Veldhuis JD
J Clin Endocrinol Metab; 1989 Nov; 69(5):1053-8. PubMed ID: 2507569
[TBL] [Abstract][Full Text] [Related]
9. Effect of growth hormone administration frequency on 24-hour growth hormone profiles and levels of other growth related parameters in girls with Turner's syndrome. Dutch Working Group on Growth Hormone.
van Teunenbroek A; de Muinck Keizer-Schrama SM; Stijnen T; Mouton JW; Blum WF; Mercado M; Baumann G; Drop SL
Clin Endocrinol (Oxf); 1993 Jul; 39(1):77-84. PubMed ID: 7688672
[TBL] [Abstract][Full Text] [Related]
10. Plasma growth hormone-binding protein activity, insulin-like growth factor I, and its binding protein levels in patients with Turner's syndrome: effect of short- and long-term recombinant human growth hormone administration.
Saggese G; Federico G; Cinquanta L
Pediatr Res; 1995 Jan; 37(1):106-11. PubMed ID: 7535419
[TBL] [Abstract][Full Text] [Related]
11. Effects of acute high dose and chronic low dose estrogen on plasma somatomedin-C and growth in patients with Turner's syndrome.
Copeland KC
J Clin Endocrinol Metab; 1988 Jun; 66(6):1278-82. PubMed ID: 3372687
[TBL] [Abstract][Full Text] [Related]
12. Comparative study of the changes in insulin-like growth factor-I, procollagen-III N-terminal extension peptide, bone Gla-protein, and bone mineral content in children with Turner's syndrome treated with recombinant growth hormone.
Bergmann P; Valsamis J; Van Perborgh J; De Schepper J; Van Vliet G
J Clin Endocrinol Metab; 1990 Dec; 71(6):1461-7. PubMed ID: 2229302
[TBL] [Abstract][Full Text] [Related]
13. Insulin, insulin-like growth factor-binding protein-1, and sex hormone-binding globulin in patients with Turner's syndrome: course over age in untreated patients and effect of therapy with growth hormone alone and in combination with oxandrolone.
Haeusler G; Schmitt K; Blümel P; Plöchl E; Waldhör T; Frisch H
J Clin Endocrinol Metab; 1996 Feb; 81(2):536-41. PubMed ID: 8636264
[TBL] [Abstract][Full Text] [Related]
14. Influence of spontaneous or induced puberty on the growth promoting effect of treatment with growth hormone in girls with Turner's syndrome.
Massa G; Maes M; Heinrichs C; Vandeweghe M; Craen M; Vanderschueren-Lodeweyckx M
Clin Endocrinol (Oxf); 1993 Mar; 38(3):253-60. PubMed ID: 8458097
[TBL] [Abstract][Full Text] [Related]
15. Age-related perception of stature, acceptance of therapy, and psychosocial functioning in human growth hormone-treated girls with Turner's syndrome.
Lagrou K; Xhrouet-Heinrichs D; Heinrichs C; Craen M; Chanoine JP; Malvaux P; Bourguignon JP
J Clin Endocrinol Metab; 1998 May; 83(5):1494-501. PubMed ID: 9589645
[TBL] [Abstract][Full Text] [Related]
16. Glucose turnover and insulin clearance after growth hormone treatment in girls with Turner's syndrome.
Monti LD; Brambilla P; Caumo A; Magni F; Omati S; Nizzoli G; di Natale B; Galli-Kienle M; Cobelli C; Chiumello G; Pozza G
Metabolism; 1997 Dec; 46(12):1482-8. PubMed ID: 9439548
[TBL] [Abstract][Full Text] [Related]
17. Growth hormone bioactivity in girls with Turner's syndrome: correlation with insulin-like growth factor I.
Foster CM; Borondy M; Markovs ME; Hopwood NJ; Kletter GB; Beitins IZ
Pediatr Res; 1994 Feb; 35(2):218-22. PubMed ID: 7513079
[TBL] [Abstract][Full Text] [Related]
18. Comparison of four computerized models to estimate 24-hour growth hormone secretion in girls with Turner's syndrome.
Kuilboer MM; Kleijer B; Kamp GA; Veldhuis JD; Johnson ML; Wit JM
Horm Res; 1992; 38(3-4):125-33. PubMed ID: 1306843
[TBL] [Abstract][Full Text] [Related]
19. Growth-promoting effect of growth hormone and low dose ethinyl estradiol in girls with Turner's syndrome.
Vanderschueren-Lodeweyckx M; Massa G; Maes M; Craen M; van Vliet G; Heinrichs C; Malvaux P
J Clin Endocrinol Metab; 1990 Jan; 70(1):122-6. PubMed ID: 2294126
[TBL] [Abstract][Full Text] [Related]
20. Growth hormone therapy in Turner's syndrome: an update on final height. Genentech National Cooperative Study Group.
Rosenfeld RG
Acta Paediatr Suppl; 1992 Sep; 383():3-6; discussion 7. PubMed ID: 1458013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
